fashion -WSS

fashion

author：Wikipedia 2025-08-11 08:00:47 - browse：8

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Elisabeth Bik tackles the widespread issue of research misconduct

WSS

Juul documents reveal insider tactics on political lobbying

Medicare Advantage isn’t working — for anyone

Latigo launches with $135 million for Vertex

Pfizer is about to make a big push in cancer. Will investors listen?

Congress considering partial increase for doctor pay in Medicare

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

fashion

entertainment

How to save PrEP access — and even expand it

AMAs digital advisors table RPM coding reform proposal, again

Supreme Court strikes down use of affirmative action

Virtual repurposing can help discover new uses for existing drugs

United colonoscopy coverage change 'may cost lives,' doctors say

Bernie Sanders gets little from pharma CEOs on drug prices

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Childhood vaccination ad campaign launches in the U.K.

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Wikipedia

Study gives hint on South Asians’ higher risk of cardiovascular disease

Childhood vaccination ad campaign launches in the U.K.

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Long Covid research funding gets a major boost from NIH

Doctors on social media are being harassed and cyberbullied

Children’s Hospital revives plan for pedestrian bridge

explore

hotspot

leisure time

leisure time